Antitumor effects of arsenic trioxide in transformed human thyroid cells

Thyroid

Volumn 18, Issue 11, 2008, Pages 1183-1193

  Fröhlich, Eleonore ^a   Czarnocka, Barbara ^b   Brossart, Peter ^a   Wahl, Richard ^a,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF WARSAW   (Poland)

^c Diagnostic Radiology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUTATHIONE; IODIDE; PENDRIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; SODIUM IODIDE SYMPORTER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG MECHANISM; GENETIC TRANSCRIPTION; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CELL; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA, FOLLICULAR; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BIOLOGICAL TRANSPORT, ACTIVE; CARCINOMA, PAPILLARY; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GLUCOSE; GLUTATHIONE; HUMANS; IODIDES; IODINE RADIOISOTOPES; ONCOGENE PROTEIN V-AKT; OXIDES; RADIATION TOLERANCE; REACTIVE OXYGEN SPECIES; THYROID NEOPLASMS;

EID: 56549104759     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2008.0114     Document Type: Article

References (67)

1. Dragoiescu C, Hoekstra OS, Kuik DJ, Lips P, Plaizier MA, Rodrigus PT, Huijsmans DA, Ribot JG, Kuijpens J, Coebergh JW, Teule GJ 2003 Feasibility of a randomized trial on adjuvant radio-iodine therapy in differentiated thyroid cancer. Clin Endocrinol (Oxf) 58:451-455.
2. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C 2006 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926-932.
3. Simon D, Köhrle J, Schmutzler C, Mainz K, Reiners C, Roher H 1996 Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results. Exp Clin Endocrinol Diabetes 104 Suppl 4:13-15.
4. Grunwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, Risse J, Biersack HJ 1998 Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 39:1903-1906.
5. Kaniewski M, Czetwertynska M, Godlewska P, Drac-Kaniewska J 2001 Non-iodine-absorbing metastasis of differentiated thyroid cancer - therapeutic probe with 13-cis retinoic acid. Wiad Lek 54:297-300.
6. Schmutzler C, Kohrle J 2000 Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 10:393-406.
7. Bergstrom SK, Gillan E, Quinn JJ, Altman AJ 1998 Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report. J Pediatr Hematol Oncol 20:545-547.
8. 3 exerts dose-dependent dual effects on APL cells. Blood 89:3345-3353.
9. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354-3360.
10. Yang CH, Kuo ML, Chen JC, Chen YC 1999 Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 81:796-799.
11. 3) in the orthotopic metastasis model of androgenin-dependent prostate cancer. Cancer Res 61:5432-5440.
12. 3). FEBS Lett 519:195-200.
13. Vuky J, Yu R, Schwartz L, Motzer RJ 2002 Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest New Drugs 20:327-330.
14. 3) in the treatment of acute promyelocytic leukemia. J Biol Regul Homeost Agents 13:195-200.
15. Gallagher R, Ferrari A, Kaubisch A, Makower D, Stein C, Rajdev L, Gucalp R, Wadler S, Mandeli J, Sarta C 2004 Arsenic trioxide (ATO) in metastatic hormone-refractory prostate cancer (HRPC): results of phase II trial T99-0077. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 22:4638.
16. Zhang J, Wang B 2006 Arsenic trioxide (As(2)O(3)) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo. Gynecol Oncol 103:199-206.
17. Miller WH, Jr. 2002 Molecular targets of arsenic trioxide in malignant cells. Oncologist 7:14-19.
18. 3 is associated with the inherent cellular level of reactive oxygen species. World J Gastroenterol 8:36-39.
19. Hour TC, Huang CY, Lin CC, Chen J, Guan JY, Lee JM, Pu YS 2004 Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide. Anticancer Drugs 15:779-785.
20. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD, Saji M 2001 Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 61:6105-6111.
21. Wahl R, Brossart P, Eizenberger D, Schuch H, Kallee E 1992 Direct effects of protirelin (TRH) on cultured porcine thyrocytes. J Endocrinol Invest 15:345-351.
22. Frohlich E, Macchicao F, Wahl R 2005 Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr Relat Cancer 12:1-13.
23. Skubis-Zegadlo J, Nikodemska A, Przytula E, Mikula M, Bardadin K, Ostrowski J, Wenzel BE, Czarnocka B 2005 Expression of pendrin in benign and malignant human thyroid tissues. Br J Cancer 93:144-151.
24. Eckle VS, Buchmann A, Bursch W, Schulte-Hermann R, Schwarz M 2004 Immunohistochemical detection of activated caspases in apoptotic hepatocytes in rat liver. Toxicol Pathol 32:9-15.
25. Bidart JM, Mian C, Lazar V, Russo D, Filetti S, Caillou B, Schlumberger M 2000 Expression of pendrin and the Pendred syndrome (PDS) gene in human thyroid tissues. J Clin Endocrinol Metab 85:2028-2033.
26. Griffin RJ, Williams BW, Park HJ, Song CW 2005 Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy. Int J Radiat Oncol Biol Phys 61:1516-1522.
27. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP, Jr., Rafii S 2000 Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 96:1525-1530.
28. Wang Y, Hu Y, Sun C, Zhang X, He W 2006 Mechanism of arsenic trioxide inhibiting angiogenesis in multiple myeloma. J Huazhong Univ Sci Technolog Med Sci 26:43-46.
29. Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, Munshi NC, Waxman S, Anderson KC 2002 Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 1:851-860.
30. Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, de Cesaris MG, Surico N, Malavasi F, Ferrero E 2002 Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat 73:61-73.
31. Derwahl M, Kuemmel M, Goretzki P, Schatz H, Broecker M 1993 Expression of the human TSH receptor in a human thyroid carcinoma cell line that lacks an endogenous TSH receptor: growth inhibition by cAMP. Biochem Biophys Res Commun 191:1131-1138.
32. Kurebayashi J, Tanaka K, Otsuki T, Moriya T, Kunisue H, Uno M, Sonoo H 2000 All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab 85:2889-2896.
33. Demeure MJ, Doffek KM, Wilson SD 1997 Defective thyrotropin receptor G-protein cyclic adenosine monophosphate signaling mechanism in the FTC human follicular thyroid cancer cell line. Surgery 122:1195-1201; discussion 1201-1202.
34. Kimura H, Yamashita S, Namba H, Usa T, Fujiyama K, Tsuruta M, Yokoyama N, Izumi M, Nagataki S 1992 Impairment of the TSH signal transduction system in human thyroid carcinoma cells. Exp Cell Res 203:402-406.
35. Brabant G 2008 Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? J Clin Endocrinol Metab 93:1167-1169.
36. Schmutzler C, Winzer R, Meissner-Weigl J, Kohrle J 1997 Retinoic acid increases sodium=iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 240:832-838.
37. Provenzano MJ, Fitzgerald MP, Krager K, Domann FE 2007 Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC). Otolaryngol Head Neck Surg 137:722-728.
38. Puppin C, D'Aurizio F, D'Elia AV, Cesaratto L, Tell G, Russo D, Filetti S, Ferretti E, Tosi E, Mattei T, Pianta A, Pellizzari L, Damante G 2005 Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology 146:3967-3974.
39. Royaux IE, Suzuki K, Mori A, Katoh R, Everett LA, Kohn LD, Green ED 2000 Pendrin, the protein encoded by the Pendred syndrome gene (PDS), is an apical porter of iodide in the thyroid and is regulated by thyroglobulin in FRTL-5 cells. Endocrinology 141:839-845.
40. Mian C, Lacroix L, Alzieu L, Nocera M, Talbot M, Bidart JM, Schlumberger M, Caillou B 2001 Sodium iodide symporter and pendrin expression in human thyroid tissues. Thyroid 11:825-830.
41. Gillam MP, Sidhaye AR, Lee EJ, Rutishauser J, Stephan CW, Kopp P 2004 Functional characterization of pendrin in a polarized cell system. Evidence for pendrin-mediated apical iodide efflux. J Biol Chem 279:13004-13010.
42. Rousset B 2007 How iodide reaches its site of utilisation in the thyroid gland - involvement of solute carrier 26A4 (pendrin) and solute carrier 5A8 (apical iodide transporter). In: Hughes T, Dunn C, McCulloch A (eds) European Endocrine Disease 2007, www.touchbriefings.com, London, pp 81-83.
43. Saito T, Endo T, Kawaguchi A, Ikeda M, Katoh R, Kawaoi A, Muramatsu A, Onaya T 1998 Increased expression of the sodium=iodide symporter in papillary thyroid carcinomas. J Clin Invest 101:1296-1300.
44. Choi YJ, Park JW, Suh SI, Mun KC, Bae JH, Song DK, Kim SP, Kwon TK 2002 Arsenic trioxide-induced apoptosis in U937 cells involve generation of reactive oxygen species and inhibition of Akt. Int J Oncol 21:603-610.
45. Mandal M, Kim S, Younes MN, Jasser SA, El-Naggar AK, Mills GB, Myers JN 2005 The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer 92:1899-1905.
46. Goto S, Yoshida K, Morikawa T, Urata Y, Suzuki K, Kondo T 1995 Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells. Cancer Res 55:4297-4301.
47. Knoll N, Ruhe C, Veeriah S, Sauer J, Glei M, Gallagher EP, Pool-Zobel BL 2005 Genotoxicity of 4-hydroxy-2-nonenal in human colon tumor cells is associated with cellular levels of glutathione and the modulation of glutathione S-transferase A4 expression by butyrate. Toxicol Sci 86:27-35.
48. Lu SC, Sun WM, Yi J, Ookhtens M, Sze G, Kaplowitz N 1996 Role of two recently cloned rat liver GSH transporters in the ubiquitous transport of GSH in mammalian cells. J Clin Invest 97:1488-1496.
49. Sze G, Kaplowitz N, Ookhtens M, Lu SC 1993 Bidirectional membrane transport of intact glutathione in Hep G2 cells. Am J Physiol 265:G1128-G1134.
50. Wu XX, Ogawa O, Kakehi Y 2004 Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine. Int J Oncol 24:1489-1497.
51. Davison K, Cote S, Mader S, Miller WH 2003 Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 17:931-940.
52. Jan KY, Wang TC, Ramanathan B, Gurr JR 2006 Dithiol compounds at low concentrations increase arsenite toxicity. Toxicol Sci 90:432-439.
53. Dreher I, Schmutzler C, Jakob F, Kohrle J 1997 Expression of selenoproteins in various rat and human tissues and cell lines. J Trace Elem Med Biol 11:83-91.
54. Yeh JY, Cheng LC, Ou BR, Whanger DP, Chang LW 2002 Differential influences of various arsenic compounds on glutathione redox status and antioxidative enzymes in porcine endothelial cells. Cell Mol Life Sci 59:1972-1982.
55. Yasuda M, Ogane N, Hayashi H, Kameda Y, Miyagi Y, Iida T, Mori Y, Tsukinoki K, Minematsu T, Osamura Y 2005 Glucose transporter-1 expression in the thyroid gland: clinicopathological significance for papillary carcinoma. Oncol Rep 14:1499-1504.
56. Liu Z, Sanchez MA, Jiang X, Boles E, Landfear SM, Rosen BP 2006 Mammalian glucose permease GLUT1 facilitates transport of arsenic trioxide and methylarsonous acid. Biochem Biophys Res Commun 351:424-430.
57. Ciampi R, Vivaldi A, Piampiani P, Agate L, Salvadori P, Del Guerra A, Pinchera A, Elisei R 2007 Characterization of facilitative glucose transporters (GLUT) in human thyroid carcinoma cell lines. Endocrine Abstracts 14:P345.
58. Castiglione S, Fanciulli M, Bruno T, Evangelista M, Del Carlo C, Paggi MG, Chersi A, Floridi A 1993 Rhein inhibits glucose uptake in Ehrlich ascites tumor cells by alteration of membrane-associated functions. Anticancer Drugs 4:407-414.
59. Vera JC, Reyes AM, Carcamo JG, Velasquez FV, Rivas CI, Zhang RH, Strobel P, Iribarren R, Scher HI, Slebe JC, Golde DW 1996 Genistein is a natural inhibitor of hexose and dehydroascorbic acid transport through the glucose transporter, GLUT1. J Biol Chem 271:8719-8724.
60. Walle T, Walle UK 2003 The beta-D-glucoside and sodium-dependent glucose transporter 1 (SGLT1)-inhibitor phloridzin is transported by both SGLT1 and multidrug resistance-associated proteins 1/2. Drug Metab Dispos 31:1288-1291.
61. Woo SY, Lee MY, Jung YJ, Yoo ES, Seoh JY, Shin HY, Ahn HS, Ryu KH 2006 Arsenic trioxide inhibits cell growth in SH-SY5Y and SK-N-AS neuroblastoma cell lines by a different mechanism. Pediatr Hematol Oncol 23:231-243.
62. Ai Z, Lu W, Ton S, Liu H, Sou T, Shen Z, Qin X 2007 Arsenic trioxide-mediated growth inhibition in gallbladder carcinoma cells via down-regulation of Cyclin D1 transcription mediated by Sp1 transcription factor. Biochem Biophys Res Commun 360:684-689.
63. 3. Arch Toxicol 63:419-422.
64. Li JQ, Li Y, Shi YJ, Wu SL 2004 [Re-expression of p16 gene in myeloma cell line U266 by arsenic trioxide]. Ai Zheng 23:626-630.
65. Ye XS, Liu T, Cui X, Meng WT, Xi YM 2007 [Methylation of P15INK4B gene in patients with myelodysplastic syndromes and demethylating effects of drugs]. Sichuan Da Xue Xue Bao Yi Xue Ban 38:57-59.
66. Davis CD, Uthus EO, Finley JW 2000 Dietary selenium and arsenic affect DNA methylation in vitro in Caco-2 cells and in vivo in rat liver and colon. J Nutr 130:2903-2909.
67. Cui X, Wakai T, Shirai Y, Yokoyama N, Hatakeyama K, Hirano S 2006 Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells. Hum Pathol 37:298-311.